Home » Stocks » Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (MIST)

Stock Price: $7.15 USD 0.01 (0.14%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 176.68M
Revenue (ttm) n/a
Net Income (ttm) -60.44M
Shares Out 24.71M
EPS (ttm) -2.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $7.15
Previous Close $7.14
Change ($) 0.01
Change (%) 0.14%
Day's Open 7.08
Day's Range 7.08 - 7.39
Day's Volume 62,327
52-Week Range 1.69 - 23.25

More Stats

Market Cap 176.68M
Enterprise Value 91.54M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.71M
Float 13.03M
EPS (basic) -2.35
EPS (diluted) -2.46
FCF / Share -2.43
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 464,096
Short Ratio 2.43
Short % of Float 3.56%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.00
Revenue n/a
Operating Income -62.48M
Net Income -60.44M
Free Cash Flow -59.94M
Net Cash 85.14M
Net Cash / Share 3.45
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -31.88%
ROE -51.81%
ROIC -430.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(85.31% upside)
Current: $7.15
Target: 13.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-57.88-23.82-8.27
Net Income-55.23-23.19-8.09
Shares Outstanding15.780.320.24
Earnings Per Share-3.50-72.63-34.15
Operating Cash Flow-51.15-21.05-8.05
Capital Expenditures-0.41-0.01-0.04
Free Cash Flow-51.57-21.05-8.09
Cash & Equivalents12085.9826.91
Total Debt0.51--
Net Cash / Debt11985.9826.91
Book Value115-55.21-33.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Milestone Pharmaceuticals Inc.
Country Canada
Employees 28
CEO Joseph G. Oliveto

Stock Information

Ticker Symbol MIST
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MIST


Milestone Pharmaceuticals, a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.